Education
About Us
Working with TipRanks
Follow Us
Eupraxia Pharmaceuticals (TSE:EPRX)
TSX:EPRX
EPRX Stock Chart & Stats
C$12.47
C$0.00(0.00%)
At close: 4:00 PM EST
C$12.47
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$3.96 - C$12.86
Previous CloseN/A
Volume2.50K
Average Volume (3M)53.43K
Market Cap
C$632.45M
Enterprise ValueC$320.28M
Total Cash (Recent Filing)C$123.78M
Total Debt (Recent Filing)C$237.38K
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Mar 31, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding50,648,330
10 Day Avg. Volume45,847
30 Day Avg. Volume53,430
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)4.58
Price to Sales (P/S)0.00
P/FCF Ratio-5.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$21.60Price Target Upside73.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyAnalyst reports initial RESOLVE data show substantial improvements in esophageal tissue health and high rates of clinical remission after a single administration of EP-104GI, indicating strong per-patient efficacy.
Dosing And AdherenceAnalyst notes sustained symptom improvement and a delivery profile that may allow infrequent dosing, which could enhance patient adherence compared with weekly biologics or daily steroid regimens.
Safety ProfileAnalyst highlights a favorable safety profile with low systemic exposure, no serious adverse events observed, and no reported oral yeast infections, suggesting a broader safety window for chronic use.
Bears Say
Adverse Event RiskAnalyst cautions that observed rates of esophageal candidiasis in short-duration clinical testing raise safety and tolerability concerns that may constrain adoption and require additional risk mitigation.
Physician Awareness And Commercial UptakeAnalyst points out limited clinician familiarity with EP-104GI, as only a minority of surveyed gastroenterologists reported strong awareness, which could slow commercial uptake.
Study Size And Trial ValidationAnalyst warns small early-stage cohort sizes create uncertainty and that randomized, controlled trials will be required to validate the observed efficacy and durability.
Eupraxia Pharmaceuticals News
EPRX FAQ
What was Eupraxia Pharmaceuticals’s price range in the past 12 months?
Eupraxia Pharmaceuticals lowest stock price was C$3.96 and its highest was C$12.86 in the past 12 months.
What is Eupraxia Pharmaceuticals’s market cap?
Eupraxia Pharmaceuticals’s market cap is C$632.45M.
When is Eupraxia Pharmaceuticals’s upcoming earnings report date?
Eupraxia Pharmaceuticals’s upcoming earnings report date is Mar 31, 2026 which is in 66 days.
How were Eupraxia Pharmaceuticals’s earnings last quarter?
Eupraxia Pharmaceuticals released its earnings results on Nov 04, 2025. The company reported -C$0.268 earnings per share for the quarter, missing the consensus estimate of -C$0.249 by -C$0.019.
Is Eupraxia Pharmaceuticals overvalued?
According to Wall Street analysts Eupraxia Pharmaceuticals’s price is currently Undervalued.
Does Eupraxia Pharmaceuticals pay dividends?
Eupraxia Pharmaceuticals does not currently pay dividends.
What is Eupraxia Pharmaceuticals’s EPS estimate?
Eupraxia Pharmaceuticals’s EPS estimate is -0.19.
How many shares outstanding does Eupraxia Pharmaceuticals have?
Eupraxia Pharmaceuticals has 50,648,330 shares outstanding.
What happened to Eupraxia Pharmaceuticals’s price movement after its last earnings report?
Eupraxia Pharmaceuticals reported an EPS of -C$0.268 in its last earnings report, missing expectations of -C$0.249. Following the earnings report the stock price went up 3.097%.
Which hedge fund is a major shareholder of Eupraxia Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:EPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eupraxia Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$21.60 (73.23% Upside)
C$21.60 (73.23% Upside)
Insider Transactions
Bought Shares
Worth C$143.9K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
135.71%
12-Months-Change
Fundamentals
Return on Equity
-59.46%
Trailing 12-Months
Asset Growth
-5.79%
Trailing 12-Months
Company Description
Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
EPRX Stock 12 Month Forecast
Average Price Target
C$21.60
▲(73.23% Upside)
Technical Analysis
NervGen Pharma
―
Entheon Biomedical
―
Bright Minds Biosciences
―
MYND Life Sciences
―
Mindbio Therapeutics Corp.
―
Ownership Overview
17.62% Insiders
―
Mutual Funds
21.13% Other Institutional Investors
61.25% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---